Endocrine therapy is recommended for IBC patients with estrogen receptor-positive (ER +) and/or progesterone receptor-positive (PR +) by the National Comprehensive Cancer Network (NCCN) guidelines. This evidence concerns the gene PGR and inflammatory breast carcinoma.